Sanofi SA (ADR) (NYSE:SNY) Adds Gene Therapy Project And $300 Million To Selecta Deal

Sanofi SA (ADR) (NYSE:SNY) has added $300 million to its collaboration with Selecta Biosciences to develop a vaccination for the treatment of celiac disease and achieve other research innovations. The company is also mulling to join hands with Genethon to making the treatments safe across diverse categories if the need arises. Selecta has also entered a joint venture with Genethon for development and research of drugs related to gene therapy. The original deal with Selecta was signed to conduct clinical trials to develop drugs for treating food allergies and type 1 diabetes. The immunotherapies vaccine particles that have been created by Selecta can help ward off the negative impact of diseases on the immune system, and Sanofi is looking forward to exploring the area.

The deal licenses Sanofi as the exclusive developer of celiac disease treatment drugs. The drug will help the immune system fight against the foods that contain gluten that are the leading cause of abdominal pain and even the intestinal cancer.

Research on Reverse Outcome of Vaccine

Talking about the so-called negative vaccines that the company is planning to develop, CEO, Werner Cautreels, said that the company was working to analyze the differing outcome of a vaccine. Having pushed the food allergies project for later, Sanofi is more eager on the current one. The company has plans for launching the initial public offering if all goes as planned and the project garners success.

Promising Partnership

As part of the deal, Sanofi SA (ADR) (NYSE:SNY) and Selecta are working on the SVP tech of the latter with a gene therapy and are looking to sharing the revenues in their success. The deal does not restrict Selecta to work only with Sanofi, and the company can also work in the gene therapy with other bioscience companies. So far, the relationship between the two companies has been great, and the road seems better ahead.

Sanofi’s Biotherapeutics Research & Development Head Kurt Stoeckli said that the gene therapy field was an ever evolving field. He said that achieving new milestones and providing better treatments is something that the partnership was all about, and they were looking forward to the results.

Please make sure to read and completely understand our disclaimer at We may be compensated for posting this content on our website by EDM Media LLC. For questions, comments or suggestions please contact

Published by Duncan Oleinic

Duncan Oleinic is from New Yourk. After graduating with a degree in physics, he began his career as an analyst in a broking firm. Through this experience he was able to advance to the role of correspondent for a U.S based financial news provider, where he worked from 2001 to 2007. He subsequently joined a merchant banking firm as a financial analyst focused on valuing unlisted companies in the sub-continent. Over the course of his two years here, he performed valuations of several media companies which were later acquired by peers.

Recent Stories

SignUp Now For Our Featured Newsletter